GLAXO.NS实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 17:59):

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally...

Stats
今日成交量	71 886.00
平均成交量	158 256
市值	352.80B
EPS	INR0 ( 2024-02-11 )
下一个收益日期	( INR0 ) 2024-05-14
Last Dividend	INR32.00 ( 2023-06-30 )
Next Dividend	INR0 ( N/A )
P/E	66.71
ATR14	INR2.22 (0.11%)

音量相关性

長: 0.03 (neutral)

短: 0.41 (neutral)

Signal:(60.351) Neutral

GlaxoSmithKline 相关性

10 最正相关
DALALSTCOM.NS	0.832

10 最负相关
LTGILTBEES.NS	-0.83
ANANDRATHI.NS	-0.821
KPIGLOBAL.NS	-0.807

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

GlaxoSmithKline 相关性 - 货币/商品

-0.17
( neutral )

0.01
( neutral )

-0.05
( neutral )

0.05
( neutral )

-0.06
( neutral )

-0.07
( neutral )

GlaxoSmithKline 财务报表

Annual	2022
营收:	INR32.52B
毛利润:	INR19.67B (60.49 %)
EPS:	INR36.05

FY	2022
营收:	INR32.52B
毛利润:	INR19.67B (60.49 %)
EPS:	INR36.05

FY	2022
营收:	INR32.78B
毛利润:	INR18.28B (55.78 %)
EPS:	INR22.48

FY	2021
营收:	INR31.99B
毛利润:	INR18.04B (56.40 %)
EPS:	INR21.14

Financial Reports:

No articles found.

GlaxoSmithKline Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR60.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR32.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

GlaxoSmithKline Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.28 - low (42.21%) | Divividend Growth Potential Score: 5.05 - Stable (1.06%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR3.50	2003-04-10
Last Dividend	INR32.00	2023-06-30
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	21	--
Total Paid Out	INR435.25	--
Avg. Dividend % Per Year	1.67%	--
Score	2.78	--
Div. Sustainability Score	4.28
Div.Growth Potential Score	5.05
Div. Directional Score	4.67	--

Next Divdend (Est)
(2025-04-07)

INR32.69 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.78

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR17.50	1.50%
2019	INR20.00	1.34%
2020	INR20.00	1.23%
2021	INR30.00	1.86%
2022	INR60.00	3.45%
2023	INR32.00	2.43%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
PREMIERPOL.NS	Dividend Junior	2023-09-11	Sporadic	9	0.39%
KAMDHENU.NS	Dividend Junior	2023-08-14	Sporadic	17	0.32%
EDELWEISS.NS	Dividend Junior	2023-09-18	Annually	17	2.38%
ADSL.NS	Dividend Junior	2023-08-10	Sporadic	16	0.91%
STERTOOLS.NS	Dividend Junior	2023-09-11	Annually	19	0.38%
NAHARCAP.NS	No Dividend Player	2023-09-08	Annually	17	0.70%
HINDWAREAP.NS	Dividend Junior	2023-09-20	Annually	5	0.09%
BSE.NS	Dividend Junior	2023-08-04	Annually	8	1.22%
REPCOHOME.NS	Dividend Junior	2023-09-07	Annually	12	0.69%
KSL.NS	Dividend Junior	2023-08-11	Sporadic	15	1.81%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.160	1.500	6.81	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.322	1.500	7.53	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	519.54	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	6.24	2.00	7.92	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.24	2.00	6.88	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.604	1.000	3.27	3.27	[0.2 - 0.8]
operatingProfitMarginTTM	0.264	1.000	6.73	6.73	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.28

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	67.01	1.000	3.33	0	[1 - 100]
returnOnEquityTTM	0.322	2.50	8.41	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.24	2.00	7.92	10.00	[0 - 30]
dividendYielPercentageTTM	1.530	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.24	2.00	7.92	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.110	1.500	5.93	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0319	1.000	-1.702	0	[0.1 - 0.5]
Total Score				5.05

GlaxoSmithKline

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.